Zymeworks Turns Down All Blue’s Hostile Bid
Zymeworks Inc's (NYSE: ZYME) board has officially turned down an unsolicited, opportunistic, non-binding proposal from an activist shareholder, All Blue Falcons.
All Blue Capital Urges Zymeworks Board To Engage With All Blue On Its Acquisition Proposal
Siddhartha Mukherjee, MD, Hematology and Oncology Medical Expert, Rhodes Scholar and Pulitzer Prize Winning Author, Recently Joined All Blue as Medical Advisor
All Blue Urges Zymeworks Board to Engage with All Blue on
Zymeworks Q1 EPS $(1.19) Beats $(1.67) Estimate
Zymeworks (NYSE:ZYME) reported quarterly losses of $(1.19) per share which beat the analyst consensus estimate of $(1.67) by 28.74 percent. This is a 36.78 percent decrease over losses of $(0.87) per share from the same
Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell
• Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
Press Release From Zymeworks Shareholder All Blue Capital Confirms Earlier-Reported News Firm’s Leadership Supports Proposed Deal With Zymeworks
Alan Barge, MD, Oncology and Biopharmaceutical Drug Development Expert, Former Head of Oncology at AstraZeneca, Recently Joined All Blue as Oncology Drug Development Advisor
Barge's Expertise and Focused Leadership
Zymeworks Amended 8-K Shows Expectation for Cost Of Restructuring: $500K Cost To Benefit Of $3.5M
As previously disclosed, Zymeworks announced and implemented the Restructuring with the target of reducing employee headcount by at least 25% across the organization by the end of 2022. Costs under the Restructuring are
70 Biggest Movers From Friday
Gainers
GTY Technology Holdings Inc. (NASDAQ: GTYH) shares climbed 115.2% to close at $6.09 as the company agreed to be acquired by GI Partners.
